Get the Stockscreener App
1.71
7.57%
-0.14
Pre-market:
1.91
0.20
+11.70%
Conduit Pharmaceuticals Inc stock is traded at $1.71, with a volume of 96,640.
It is down -7.57% in the last 24 hours and down -27.54% over the past month.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
See More
Previous Close:
$1.85
Open:
$1.82
24h Volume:
96,640
Relative Volume:
0.30
Market Cap:
$5.00M
Revenue:
-
Net Income/Loss:
$-4.21M
P/E Ratio:
-31.20
EPS:
-0.0548
Net Cash Flow:
-
1W Performance:
-9.04%
1M Performance:
-27.54%
6M Performance:
-93.56%
1Y Performance:
-99.40%
1-Day Range:
$1.70
$1.8399
1-Week Range:
$1.70
$1.90
52-Week Range:
$1.70
$306.00
Conduit Pharmaceuticals Inc Stock (CDT) Company Profile
Name
Conduit Pharmaceuticals Inc
Sector
Industry
Phone
(646) 491 9132
Address
4851 TAMIAMI TRAIL NORTH, NAPLES
Compare CDT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDT
Conduit Pharmaceuticals Inc
|
1.71 | 5.41M | 0 | -4.21M | 0 | -0.0548 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
638.90 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Conduit Pharmaceuticals Inc Stock (CDT) Latest News
Key metrics from Conduit Pharmaceuticals Inc. Equity Warrant’s quarterly dataFree Chart Breakout Buy Signal Detection - Newser
Statistical indicators supporting Conduit Pharmaceuticals Inc.’s strengthSwing Trade Entry and Exit Point Analysis - Newser
What candlestick patterns are forming on Conduit Pharmaceuticals Inc. Equity WarrantRapid Trade Forecast Based on Indicators - Newser
Does Conduit Pharmaceuticals Inc. fit your quant trading modelSummary of Reliable Long-Term Trade Models - Newser
How to monitor Conduit Pharmaceuticals Inc. with trend dashboardsLong-Term Investment Strategy Summary Guide - Newser
Is it time to cut losses on Conduit Pharmaceuticals Inc.Equity Portfolio Outlook and Performance Summary - Newser
Can volume confirm reversal in Conduit Pharmaceuticals Inc.Free Short Term High Yield Stock Tips - Newser
Will breakout in Conduit Pharmaceuticals Inc. Equity Warrant lead to full recoveryAutomated AI Forecast with Trading Alerts - Newser
How Conduit Pharmaceuticals Inc. Equity Warrant stock performs during market volatilityHigh Win Rate Strategy with Stop Protection - Newser
Real time scanner hits for Conduit Pharmaceuticals Inc. Equity Warrant explainedRisk-Managed Swing Setup and Signal Analysis - Newser
What momentum shifts mean for Conduit Pharmaceuticals Inc. Equity WarrantSector Rotation Outlook With Historical Summary - Newser
Intraday Charts Show Spike in Conduit Pharmaceuticals Inc. ActivityAI Forecast for Trending Stocks Indicates Upside - beatles.ru
How to use a screener to detect Conduit Pharmaceuticals Inc. breakoutsFree Triple Digit Growth Focused Trade Plan - Newser
Published on: 2025-08-09 04:41:32 - Newser
Published on: 2025-08-08 23:58:05 - Newser
Conduit Pharmaceuticals Rebrands to CDT Equity Inc. - TipRanks
Conduit Pharmaceuticals to rename as CDT Equity Inc. - AInvest
Will Conduit Pharmaceuticals Inc. Equity Warrant stock recover after recent dropFree AI Based High Gain Watchlist Scanner - Newser
Conduit to change name to CDT Equity - MSN
Published on: 2025-08-05 21:29:13 - Newser
Leading vs lagging indicators on Conduit Pharmaceuticals Inc. performanceMinimal Risk Growth Investment Opportunity Analysis - Newser
Conduit Pharmaceuticals Changes Name to CDT Equity Inc. - AInvest
CDT Equity Inc. Emerges as Biotech Development Company with Evolved Strategy - AInvest
Conduit to Change Name to CDT Equity Inc. - FinancialContent
Conduit Pharmaceuticals Inc. Equity Warrant stock chart pattern explainedFree Risk Controlled Short Term Trade Plans - Newser
Price Consolidation Hints at Upcoming Move in Conduit Pharmaceuticals Inc.Step-by-Step Stock Investment Guide Gains Popularity - beatles.ru
How does Conduit Pharmaceuticals Inc. Equity Warrant generate profit in a changing economyMaster stock selection with insider knowledge - Jammu Links News
Is Conduit Pharmaceuticals Inc. Equity Warrant a growth stock or a value stockUnlock the power of real-time market data - Jammu Links News
What is the dividend policy of Conduit Pharmaceuticals Inc. stockPhenomenal capital gains - Jammu Links News
What analysts say about Conduit Pharmaceuticals Inc. stockGet timely advice on market trends - Jammu Links News
What drives Conduit Pharmaceuticals Inc. stock priceUnlock exclusive trading strategies for gains - Jammu Links News
What is Conduit Pharmaceuticals Inc. Equity Warrant company’s growth strategyBuild wealth faster with disciplined trading - Jammu Links News
How many analysts rate Conduit Pharmaceuticals Inc. as a “Buy”Expert guidance for superior capital growth - Jammu Links News
When is Conduit Pharmaceuticals Inc. stock expected to show significant growthExplosive capital appreciation - Jammu Links News
Why is Conduit Pharmaceuticals Inc. stock attracting strong analyst attentionBuild wealth faster with high-performing stocks - Jammu Links News
Should I hold or sell Conduit Pharmaceuticals Inc. Equity Warrant stock in 2025Double-digit growth - Jammu Links News
Is it the right time to buy Conduit Pharmaceuticals Inc. stockAchieve rapid growth with smart investments - Jammu Links News
What makes Conduit Pharmaceuticals Inc. Equity Warrant stock price move sharplyGet real-time updates on market trends - Jammu Links News
Can technical indicators confirm Conduit Pharmaceuticals Inc. Equity Warrant’s reversalROI Focused Setup Screener With Exit Markers - Newser
How strong is Conduit Pharmaceuticals Inc. Equity Warrant company’s balance sheetUnlock powerful investment tools for free - Jammu Links News
Conduit Pharmaceuticals Inc. Equity Warrant Stock Analysis and ForecastBuild wealth faster with consistent investment plans - Jammu Links News
Published on: 2025-08-03 15:04:44 - Jammu Links News
How does Conduit Pharmaceuticals Inc. Equity Warrant compare to its industry peersMaximize gains with timely market signals - Jammu Links News
What drives Conduit Pharmaceuticals Inc. Equity Warrant stock priceAchieve rapid financial growth with expert picks - Jammu Links News
What catalysts could drive Conduit Pharmaceuticals Inc. Equity Warrant stock higher in 2025Maximize returns with timely market signals - Jammu Links News
How does Conduit Pharmaceuticals Inc. compare to its industry peersExponentially increasing returns - Jammu Links News
What is the risk reward ratio of investing in Conduit Pharmaceuticals Inc. stockOutstanding capital returns - Jammu Links News
Should I hold or sell Conduit Pharmaceuticals Inc. stock in 2025Unlock your portfolio’s full growth potential - Jammu Links News
How many analysts rate Conduit Pharmaceuticals Inc. Equity Warrant as a “Buy”Accelerated wealth expansion - Jammu Links News
What catalysts could drive Conduit Pharmaceuticals Inc. stock higher in 2025Free Smart Trading Workshop - Jammu Links News
What are Conduit Pharmaceuticals Inc. company’s key revenue driversRetirement Planning Tips With Low Risk - Jammu Links News
Conduit Pharmaceuticals Inc Stock (CDT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):